NTVPet Doc: Immunotherapy for fighting cancerNTVanswer: most people would say yes but immunotherapy was first developed about on hundred years ago, and it had some degree of success at that time. Unfortunately, immunotherapy research was put on indefin… Continue reading
Medical Xpress |
Consolidation Immunotherapy in Locally Advanced NSCLC
Targeted Oncology Jyoti Patel, MD: This patient illustrates, really, what I’ve started to do in my practice. For patients who are eligible for checkpoint blockade because they don’t have a history of autoimmune disease, they don’t have HIV, and they’re otherwise well … Researchers find promising treatment strategy for stage 1-3 NSCL cancer patientsMedical Xpress SU2C researchers find promising treatment strategy for stage 1-3 NSCL cancer patientsEurekAlert (press release) |
Business Insider |
Merck, Bristol-Myers immunotherapies impress in key lung cancer trials
Reuters (Reuters) – Merck & Co’s immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone in newly-diagnosed patients with advanced non-small cell lung cancer in a highly-anticipated study that appears to … ‘We are going to have lung cancer patients living longer and better’: A new kind of cancer treatment is about to …Business Insider Merck lung cancer trial boosts immunotherapy hopesFinancial Times |
Business Insider UK |
‘We are going to have lung cancer patients living longer and better:’ A new kind of cancer treatment is about to …
Business Insider UK In data presented Monday at the American Association of Cancer Research’s annual meeting, cancer drugmakers showed that the use of immunotherapy in combination with other drugs did a better job of treating lung cancer than chemotherapy alone. The … Adding Merck’s Keytruda To Chemo Halves Death Risk For Lung Cancer PatientsForbes |
Telegraph.co.uk |
Immunotherapy-first cancer treatment a ‘game-changer’, say scientists
Telegraph.co.uk Oncologists at Johns Hopkins University and the Memorial Sloan Kettering Cancer Center administered the immunotherapy drug nivolumab over several weeks to 21 patients with non-small-cell lung cancer prior to surgery. They found the strategy was not … |